MacroGenics, Inc. (MGNX) Stock Price

MGNXStock

$4.17+137.87%52W

Market Cap$265.63M

P/E—

PEG Ratio—

Div yield—

Beta1.18

MGNX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)125.22%

Price vs S&P 500 (4W)1.36%

VGM Score59.42

Book Value / Share (Quarterly)$0.33

P/TBV (Annual)3.28x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.53%

Cash Flow / Share (Quarterly)$-1.13

Price vs S&P 500 (YTD)137.73%

Gross Margin (TTM)74.45%

Net Profit Margin (TTM)-44.79%

EPS (TTM)$-1.11

10-Day Avg Trading Volume0.56M

EPS Excl Extra (TTM)$-1.11

Revenue Growth (5Y)7.34%

EPS (Annual)$-1.18

ROI (Annual)-59.42%

Gross Margin (Annual)75.91%

Net Profit Margin (5Y Avg)-89.99%

Cash / Share (Quarterly)$2.43

Revenue Growth QoQ (YoY)57.48%

ROA (Last FY)-29.05%

Revenue Growth TTM (YoY)1.97%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-73.32%

Operating Margin (TTM)-40.53%

Cash Flow / Share (Annual)$-1.31

P/B Ratio12.23x

P/B Ratio (Quarterly)8.67x

Net Income / Employee (Annual)$-254,700

EV / Revenue (TTM)1.66x

Net Interest Coverage (TTM)-13.74x

ROA (TTM)-28.40%

EPS Growth QoQ (YoY)-70.10%

EV / EBITDA (TTM)4.75x

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)5.10x

Quick Ratio (Quarterly)1.72x

3-Month Avg Trading Volume0.99M

52-Week Price Return137.87%

Revenue / Employee (TTM)$536,100

Tangible BV / Share (Quarterly)$3.13

P/S Ratio (Annual)1.73x

Asset Turnover (Annual)0.58x

52-Week High$5.08

Operating Margin (5Y Avg)-93.94%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-20.19%

Tangible BV CAGR (5Y)-13.85%

26-Week Price Return136.47%

Quick Ratio (Annual)4.71x

13-Week Price Return-5.19%

Total Debt / Equity (Annual)1.26x

Current Ratio (Quarterly)1.90x

Enterprise Value$261.53M

Revenue / Share Growth (5Y)3.41%

Asset Turnover (TTM)0.63x

Book Value / Share Growth (5Y)-30.10%

Revenue / Employee (Annual)$510,200

Inventory Turnover (Annual)9.10x

Pretax Margin (Annual)-50.36%

Cash / Share (Annual)$3.00

3-Month Return Std Dev63.55%

Gross Margin (5Y Avg)89.11%

Net Income / Employee (TTM)$-240,100

ROE (Last FY)-134.23%

Net Interest Coverage (Annual)-4.34x

EPS Basic Excl Extra (Annual)$-1.18

P/FCF (TTM)6.06x

Receivables Turnover (TTM)14.98x

EV / Free Cash Flow (TTM)3.52x

Total Debt / Equity (Quarterly)3.24x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)16.91x

ROI (TTM)-59.93%

P/S Ratio (TTM)1.65x

Pretax Margin (5Y Avg)-89.96%

Revenue / Share (Annual)$2.37

Tangible BV / Share (Annual)$2.30

Price vs S&P 500 (52W)119.56%

Year-to-Date Return149.69%

5-Day Price Return-1.71%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-32.14%

Net Profit Margin (Annual)-49.91%

Month-to-Date Return8.94%

Cash Flow / Share (TTM)$0.98

EBITD / Share (Annual)$-1.04

Operating Margin (Annual)-48.72%

LT Debt / Equity (Annual)1.26x

ROI (5Y Avg)-58.36%

LT Debt / Equity (Quarterly)3.24x

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)2.40x

P/B Ratio (Annual)1.83x

Inventory Turnover (TTM)4.24x

Pretax Margin (TTM)-45.22%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)-7.98%

Beta1.18x

P/FCF (Annual)41.43x

Revenue / Share (TTM)$2.48

ROE (TTM)-147.80%

52-Week Low$1.29

vGradeB

gGradeC

mGradeB

vgmGradeC

MGNX Earnings Surprise History

Q2 25-0.57est. 0.38

Q3 250.27est. -0.51

Q4 25-0.22est. -0.02

Q1 26-0.58est. -0.55

Q2 261.14est. 0.26

MGNX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.85

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MGNXMacroGenics, Inc.	B	C	B	$4.17
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About MacroGenics, Inc.

Macrogenics Inc. is a biotechnology company developing antibody-based therapeutics for cancer treatment. The company's marketed product, MARGENZA, is approved for metastatic HER2-positive breast cancer. Its pipeline includes three clinical-stage candidates: lorigerlimab, a bispecific DART targeting immune checkpoints PD-1 and CTLA-4; MGC026, targeting B7-H3; and MGC028, targeting ADAM9, each utilizing novel topoisomerase I inhibitor-based linker-payloads.